Recently, the China Patent Protection Association announced the "2023 Patent Intensive Product Recognition List", in which the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine developed by BIOKANGTAI's wholly-owned subsidiary Beijing Minhai Biotechnology Co. It is also one of the human vaccine products with the largest number of patents in the list.

The vaccine is the scientific research result of the major new drug creation and production project of the Ministry of Science and Technology of China, and it is also the world's first dual-carrier 13-valent pneumococcal conjugate vaccine. Minhai Biologicals has successfully researched and developed this vaccine over a period of nearly 20 years, and it has made a number of breakthrough technological innovations in the areas of polysaccharide protein conjugation, formulation, adjuvant, quality control, etc., and it has already obtained 6 patents for its invention. The vaccine has also been included in the priority review and approval varieties by the Drug Evaluation Center of the State Drug Administration, and will be approved in September 2021 for marketing.

The filing and recognition of patent-intensive products is the work of the State Intellectual Property Office in accordance with the requirements of the "Special Action Program for Patent Transformation and Utilization (2023-2025)" of the General Office of the State Council, focusing on the actual contribution of patents in enhancing the competitiveness and value-added of products, and with reference to the "Evaluation Method for Enterprise Patent-Intensive Products" (T/PPAC402-2022), the evaluation of patent-intensive products will be carried out. The unified identification is carried out in industrial fields for products with high economic benefits and outstanding contribution of patent value that have reached the evaluation benchmarks of the product classification to which they belong.

https://mp.weixin.qq.com/s/L5zzjbhcyvGiRRDxd4HicA

责编: editor